ATE320811T1 - Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors - Google Patents
Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktorsInfo
- Publication number
- ATE320811T1 ATE320811T1 AT97936371T AT97936371T ATE320811T1 AT E320811 T1 ATE320811 T1 AT E320811T1 AT 97936371 T AT97936371 T AT 97936371T AT 97936371 T AT97936371 T AT 97936371T AT E320811 T1 ATE320811 T1 AT E320811T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitors
- protease
- transcription factor
- sheet mimetics
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69242096A | 1996-08-05 | 1996-08-05 | |
US72507396A | 1996-10-02 | 1996-10-02 | |
US79791597A | 1997-02-10 | 1997-02-10 | |
US4706797P | 1997-05-19 | 1997-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE320811T1 true ATE320811T1 (de) | 2006-04-15 |
Family
ID=27489127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97936371T ATE320811T1 (de) | 1996-08-05 | 1997-08-05 | Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0915700B1 (de) |
JP (1) | JP2001524931A (de) |
KR (1) | KR20000029838A (de) |
AT (1) | ATE320811T1 (de) |
AU (1) | AU732174B2 (de) |
CA (1) | CA2262900A1 (de) |
DE (1) | DE69735545T2 (de) |
ES (1) | ES2262184T3 (de) |
NO (1) | NO990522L (de) |
NZ (1) | NZ334227A (de) |
WO (1) | WO1998005333A1 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6184223B1 (en) | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
KR20010040939A (ko) * | 1998-02-12 | 2001-05-15 | 몰레큐메틱스 리미티드 | β-시트 미메틱 및 이의 사용과 관련된 방법 |
US6323219B1 (en) | 1998-04-02 | 2001-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Methods for treating immunomediated inflammatory disorders |
US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
CA2320730A1 (en) | 1998-12-23 | 2000-07-06 | Renhua Li | Thrombin or factor xa inhibitors |
CN1353701A (zh) | 1999-01-27 | 2002-06-12 | 奥索-麦克尼尔药品公司 | 用作类胰蛋白酶抑制剂的肽基杂环酮类化合物 |
US6417189B1 (en) * | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
EP1261611A2 (de) * | 2000-02-29 | 2002-12-04 | Bristol-Myers Squibb Pharma Company | Inhibitoren der hepatitis-c-virus-ns3-protease |
US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
DE10100053A1 (de) * | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen |
US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
US7566711B2 (en) | 2001-10-12 | 2009-07-28 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US7576084B2 (en) | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US7232822B2 (en) | 2001-10-12 | 2007-06-19 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US8080657B2 (en) | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
US6884806B2 (en) | 2001-10-17 | 2005-04-26 | Bristol-Myers Squibb Company | Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
TWI286476B (en) * | 2001-12-12 | 2007-09-11 | Tibotec Pharm Ltd | Combination of cytochrome P450 dependent protease inhibitors |
WO2004035587A1 (en) | 2002-10-17 | 2004-04-29 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
WO2011096440A1 (ja) | 2010-02-03 | 2011-08-11 | PRISM BioLab株式会社 | 天然変性タンパク質に結合する化合物およびそのスクリーニング方法 |
AU2015328385B2 (en) | 2014-10-06 | 2020-06-11 | Lighthouse Pharmaceuticals, Inc. | Inhibitors of lysine gingipain |
JP6877424B2 (ja) | 2015-11-09 | 2021-05-26 | コーテクシーミー, インコーポレイテッド | アルギニンジンジパインの阻害剤 |
KR20190072530A (ko) | 2016-09-16 | 2019-06-25 | 코텍자임, 인코포레이티드 | 리신 진지파인의 케톤 억제제 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1600880A (en) * | 1978-05-23 | 1981-10-21 | Lilly Industries Ltd | Pharmaceutical compositions comprising hydantoin derivatives |
IL60617A0 (en) * | 1979-07-23 | 1980-09-16 | Sparamedica Ag | Triazolopyridazine derivative,their preparation and pharmaceutical compositions containing them |
US4594431A (en) * | 1983-08-01 | 1986-06-10 | Eli Lilly Company | Octahydroindolizinepropanoic acids and related compounds as enzyme inhibitors |
JPH0676373B2 (ja) * | 1985-12-27 | 1994-09-28 | エーザイ株式会社 | グアニジノ安息香酸エステル誘導体 |
AU653024B2 (en) * | 1991-05-30 | 1994-09-15 | Novartis Ag | Substituted diaminophthalimides and analogues |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
EE9700113A (et) * | 1994-12-22 | 1997-12-15 | Biochem Pharma Inc. | Madala molekulmassiga bitsüklilised trombiini inhibiitorid |
CZ290372B6 (cs) * | 1994-12-30 | 2002-07-17 | Celgene Corporation | Imidy jako imunoterapeutická činidla a farmaceutický prostředek tyto imidy obsahující |
EP0815123B1 (de) * | 1995-03-24 | 2001-10-04 | Molecumetics, Ltd. | Beta-schleifenähnliche verbindungen und deren verwendung als protease-inhibitoren |
WO1996030396A1 (en) * | 1995-03-24 | 1996-10-03 | Molecumetics Ltd. | β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS |
IT1277405B1 (it) * | 1995-08-01 | 1997-11-10 | Menarini Farma Ind | Derivati di lattami biciclici come inibitori della trombina |
-
1997
- 1997-08-05 JP JP50811898A patent/JP2001524931A/ja active Pending
- 1997-08-05 EP EP97936371A patent/EP0915700B1/de not_active Expired - Lifetime
- 1997-08-05 KR KR1019997000994A patent/KR20000029838A/ko not_active Application Discontinuation
- 1997-08-05 ES ES97936371T patent/ES2262184T3/es not_active Expired - Lifetime
- 1997-08-05 DE DE69735545T patent/DE69735545T2/de not_active Expired - Lifetime
- 1997-08-05 AU AU39058/97A patent/AU732174B2/en not_active Ceased
- 1997-08-05 CA CA002262900A patent/CA2262900A1/en not_active Abandoned
- 1997-08-05 AT AT97936371T patent/ATE320811T1/de not_active IP Right Cessation
- 1997-08-05 NZ NZ334227A patent/NZ334227A/xx not_active IP Right Cessation
- 1997-08-05 WO PCT/US1997/013622 patent/WO1998005333A1/en active IP Right Grant
-
1999
- 1999-02-04 NO NO990522A patent/NO990522L/no unknown
Also Published As
Publication number | Publication date |
---|---|
KR20000029838A (ko) | 2000-05-25 |
EP0915700A1 (de) | 1999-05-19 |
ES2262184T3 (es) | 2006-11-16 |
NO990522L (no) | 1999-03-30 |
DE69735545D1 (de) | 2006-05-11 |
AU3905897A (en) | 1998-02-25 |
EP0915700B1 (de) | 2006-03-22 |
WO1998005333A1 (en) | 1998-02-12 |
JP2001524931A (ja) | 2001-12-04 |
DE69735545T2 (de) | 2006-08-10 |
NZ334227A (en) | 2000-10-27 |
NO990522D0 (no) | 1999-02-04 |
CA2262900A1 (en) | 1998-02-12 |
AU732174B2 (en) | 2001-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE320811T1 (de) | Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors | |
TR200103233T2 (tr) | Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri. | |
DE60025812D1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
HK1069316A1 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
AR052921A1 (es) | Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica | |
NO20013443D0 (no) | Triazolforbindelser med dopamin-D3-reseptoraktivitet | |
DE60332137D1 (en) | Cyclohexyl-sulphone als gamma-sekretase-inhibitoren | |
ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
BR0316502A (pt) | Compostos quìmicos | |
DE69429524D1 (de) | Aminocyclohexylester und ihre anwendung | |
CY1107640T1 (el) | Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη | |
DE69529912D1 (de) | Verwendung des sekretorischen leukozytaren protease inhibitors (slpi) als tryptase-inhibitor | |
BR0109211A (pt) | Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa | |
NO971341D0 (no) | Promoter for reseptor tyrosinkinase TIE | |
ATE230414T1 (de) | Mimetika von beta-faltblatt und verfahren zur verwendung davon | |
DE69725457D1 (de) | Piperazinderivate als neurokinin-antagonisten | |
BR0014372A (pt) | Derivados de 5-hidroxissapogenina com atividade antidemência | |
EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
DE60239670D1 (de) | Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis | |
AU2932100A (en) | Neurodegenerative disorder related gene | |
ATE165594T1 (de) | Triarylethylenderivate zur therapeutischen verwendung | |
DE50202331D1 (de) | Verwendung eines phosphatadsorbers gegen gefässerkrankungen | |
NZ505980A (en) | Beta-sheet mimetics | |
EP1661566A3 (de) | Verwendung von Beta-Blatt Mimetika als Protease und Kinase Hemmer sowie als Hemmer eines Transkriptionsfaktors | |
DE69730045D1 (de) | Behandlung der harninkontinenz und zusammenstellung dafür |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |